2022 in review: Drug development milestones for tropical diseases After a pivot to studying Covid-19, several late-stage tropical disease projects picked the momentum back up in 2022.
Previously disrupted by the Covid-19 pandemic, this past year has seen a return of increased efforts and progress in the development of new treatments for tropical diseases. Spearheaded by collaborations between non-profit groups and pharma players, new treatments are edging closer to late-stage trials in malaria and neglected tropical diseases such as sleeping sickness.
API enters partnership to develop antivirals for SARS-CoV-2 variants A high-throughput drug screening platform will be developed to detect new therapies, as well as drug targets under the alliance.
Applied Pharmaceutical Innovation (API) has entered a collaboration with the University of Saskatchewan, Canada, for the discovery and development of new antivirals against emerging variants of the SARS-CoV-2 virus.
The China National Medical Products Administration (NMPA) has accepted CASI Pharmaceuticals’ partner Juventas Cell Therapy’s new drug application (NDA) of CNCT19 (Inaticabtagene Autoleucel) to treat relapsed/refractory B-cell acute lymphoblastic leukaemia (r/r B-ALL) in adults.